Nicox S.A. (EPA:ALCOX)

Market Cap	21.61M
Revenue (ttm)	7.14M
Net Income (ttm)	-20.88M
Shares Out	69.04M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,271
Average Volume	62,422
Open	0.306
Previous Close	0.314
Day's Range	0.305 - 0.313
52-Week Range	0.140 - 0.455
Beta	0.85
RSI	57.05
Earnings Date	Jan 24, 2025

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 28
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCOX

Financial Performance

In 2023, Nicox's revenue was 7.14 million, an increase of 118.33% compared to the previous year's 3.27 million. Losses were -20.88 million, -24.78% less than in 2022.